All In Biotech

NDA 203794 · Collegium Pharm INC

Nucynta

Tapentadol Hydrochloride · Oral

Discontinued

Last checked: Nov 20, 2026Latest source record: Jun 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2012

Oct 15, 2012

Approved uses

3

Original approval plus efficacy supplements

Registered trials

73

35 Phase 3, 1 recruiting

FAERS reports

28,531

26,313 serious, 19,844 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • NUCYNTA · TAPENTADOL HYDROCHLORIDE EQ 20MG BASE/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Tapentadol" as an intervention, any sponsor and status, largest first.

All 73 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death11,509
  • toxicity to various agents9,269
  • overdose5,778
  • drug abuse1,400
  • drug dependence962
  • drug withdrawal syndrome neonatal916
  • accidental overdose656
  • drug ineffective583
  • pain485
  • nausea443
  • intentional product misuse350
  • fatigue281

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20051
20081
200995
2010142
2011287
2012283
2013213
2014233
2015709
2016819
20172,271
201821,364
2019458
2020386
2021239
2022245
2023245
2024281
2025215
202644

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Nucynta (Tapentadol HCl)

2024 spending

$56.1M

Beneficiaries

9,123

53,809 claims

Per beneficiary

$6,150

$12.25 per unit

View as table
YearSpending
2020$50,695,015
2021$53,796,706
2022$57,046,571
2023$58,810,957
2024$56,108,628

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 133 on PubMed

Sponsor: Collegium Pharm INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.